Immortalized Erythroid Progenitor Cell Line for Red Blood Cell Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing artificial red blood cells from stem cells are inefficient and costly, requiring large amounts of growth factors and a long culturing period, and often produce non-erythroid cells, making it difficult to achieve stable and efficient production of enucleated red blood cells.
Innovation Solution
Establishing an immortalized human erythroid progenitor cell line by introducing an expression cassette for HPV-E6/E7 genes into human blood stem cells, which are then cultured with blood growth factors, and subsequently differentiated into enucleated red blood cells by withdrawing the external stimulus and growth factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If pluripotent stem cells are induced to differentiate into red blood cells, then red blood cells can be produced, but large amounts of growth factors are needed and the culturing period is long
Solution Approach 1:
The patent introduces an expression cassette for HPV-E6/E7 genes into human blood stem cells before differentiation induction. This preliminary genetic modification enables the cells to be immortalized and express oncogenes that promote cell proliferation, allowing the cells to maintain proliferative capacity while being induced to differentiate into red blood cells, thereby reducing the culturing period required
Solution Approach 2:
The patent changes the biological parameters of the stem cells by introducing HPV-E6/E7 oncogenes under inducible promoter control. This genetic parameter change transforms the cells into an immortalized erythroid progenitor cell line that can be rapidly expanded and differentiated, significantly improving production efficiency and reducing culturing time
2Productivity
If pluripotent stem cells are induced to differentiate into erythroid cells, then enucleated red blood cells can be obtained, but cells other than blood cells are also included requiring large culture volume
Solution Approach 1:
The patent creates a localized differentiation environment by using inducible promoters (such as tetracycline-responsive promoters) that allow spatial and temporal control of HPV-E6/E7 gene expression. This enables selective proliferation of erythroid-committed progenitor cells while suppressing differentiation into other cell types, increasing the proportion of target cells in the culture
Solution Approach 2:
The patent employs dynamic control of gene expression through inducible promoters, allowing the system to switch between proliferation phase (with HPV-E6/E7 expression) and differentiation phase (without expression). This dynamic regulation ensures high erythroid cell yield while minimizing culture volume requirements
3Manufacturing precision
If blood stem cells are induced to differentiate into erythroid cells, then red blood cells can be produced, but blood cells other than erythroid cells are also included
Solution Approach 1:
The patent performs preliminary commitment of blood stem cells to the erythroid lineage before induction of differentiation. The introduced HPV-E6/E7 expression cassette is specifically designed to be active in erythroid progenitor cells, ensuring that only erythroid-committed cells proliferate and differentiate, thereby excluding other blood cell types from the final product
Solution Approach 2:
The patent implements feedback control through inducible promoter systems that respond to cellular state. The promoter activity is regulated by cellular signals that are specific to erythroid progenitor cells, creating a feedback mechanism that maintains erythroid commitment and prevents differentiation into other cell lineages, thus improving cell purity
4Productivity
If immortalized erythroid progenitor cell line is established with HPV-E6/E7 expression, then cell proliferation is enhanced, but control of cell differentiation becomes challenging
Solution Approach 1:
The patent employs dynamic control mechanisms using inducible promoters (e.g., tetracycline-responsive promoters) that allow external regulation of HPV-E6/E7 gene expression. By adding or removing the inducing agent (doxycycline), researchers can dynamically switch between cell proliferation (with oncogene expression) and cell differentiation (without expression), making the process easy to control despite the immortalized nature of the cells
Solution Approach 2:
The patent uses an intermediary substance (inducing agent such as doxycycline) to control the expression of HPV-E6/E7 oncogenes. This intermediary acts as a switch that can be added or removed from the culture medium to control whether the cells proliferate or differentiate, providing simple and effective operational control over the differentiation process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient and stable production of enucleated red blood cells with oxygen binding and releasing abilities similar to normal red blood cells, addressing the inefficiencies and costs of previous methods and ensuring a high ratio of enucleated cells.
Implementation Method 1
introducing into human blood stem cells an expression cassette capable of inducing expression of E6 and E7 genes of human papillomavirus type 16
Data Source
AI summary
Provided are: a method for producing an immortalized human erythroid progenitor cell line, enabling efficient and stable production of enucleated red blood cells; and a method for producing human enucleated red blood cells from a human erythroid progenitor cell line obtained by the aforementioned production method. An expression cassette capable of inducing expression of HPV-E6/E7 genes in the presence of DOX was introduced into the genomic DNA of blood stem cells. Then, the blood stem cells were cultured in the presence of DOX and a blood growth factor. Thereby, immortalized cell lines of human erythroid progenitor cells were established. Further, it was revealed that culturing the cell lines under a condition where the expression of the HPV-E6/E7 genes was not induced enabled differentiation induction into enucleated red blood cells at a high ratio.